NCT00673049_2A: NCT00673049, figure 2A

NCT00673049_2AR Documentation

NCT00673049, figure 2A

Description

Kaplan-Meier digitized data from NCT00673049, figure 2A (PMID 25395283). A reported sample size of 583 for a primary endpoint of OS in lung cancer.

Usage

NCT00673049_2A

Format

A data frame of 583 observations and 3 variables:

time event time (in months)
event OS event indicator (0: no event, 1: event)
arm treatment arms (control, figitumumab)

Source

Scagliotti GV, Bondarenko I, Blackhall F, et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol 2015; 26: 497–504.

Examples

summary(NCT00673049_2A)

kmplot(NCT00673049_2A)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.